These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 9163573)

  • 1. Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist.
    Cascieri MA; Ber E; Fong TM; Hale JJ; Tang F; Shiao LL; Mills SG; MacCoss M; Sadowski S; Tota MR; Strader CD
    Eur J Pharmacol; 1997 May; 325(2-3):253-61. PubMed ID: 9163573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor.
    Cascieri MA; Ber E; Fong TM; Sadowski S; Bansal A; Swain C; Seward E; Frances B; Burns D; Strader CD
    Mol Pharmacol; 1992 Sep; 42(3):458-63. PubMed ID: 1383685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor.
    Cascieri MA; Macleod AM; Underwood D; Shiao LL; Ber E; Sadowski S; Yu H; Merchant KJ; Swain CJ; Strader CD
    J Biol Chem; 1994 Mar; 269(9):6587-91. PubMed ID: 7509807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.
    Beattie DT; Beresford IJ; Connor HE; Marshall FH; Hawcock AB; Hagan RM; Bowers J; Birch PJ; Ward P
    Br J Pharmacol; 1995 Dec; 116(8):3149-57. PubMed ID: 8719789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.
    Ciucci A; Palma C; Manzini S; Werge TM
    Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor.
    Meini S; Catalani C; Bellucci F; Cucchi P; Giuliani S; Zappitelli S; Rotondaro L; Pasqui F; Guidi A; Altamura M; Giolitti A; Maggi CA
    Eur J Pharmacol; 2005 Jun; 516(2):104-11. PubMed ID: 15925360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between binding characteristics and functional antagonism in human glioma cells by tachykinin NK1 receptor antagonists.
    Palma C; Nardelli F; Manzini S
    Eur J Pharmacol; 1999 Jun; 374(3):435-43. PubMed ID: 10422788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
    Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
    J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists.
    Rupniak NM; Tattersall FD; Williams AR; Rycroft W; Carlson EJ; Cascieri MA; Sadowski S; Ber E; Hale JJ; Mills SG; MacCoss M; Seward E; Huscroft I; Owen S; Swain CJ; Hill RG; Hargreaves RJ
    Eur J Pharmacol; 1997 May; 326(2-3):201-9. PubMed ID: 9196273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
    Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists.
    Duffy RA; Varty GB; Morgan CA; Lachowicz JE
    J Pharmacol Exp Ther; 2002 May; 301(2):536-42. PubMed ID: 11961054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
    Cascieri MA; Shiao LL; Mills SG; MacCoss M; Swain CJ; Yu H; Ber E; Sadowski S; Wu MT; Strader CD
    Mol Pharmacol; 1995 Apr; 47(4):660-5. PubMed ID: 7536886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtype- and species-selectivity of a tachykinin receptor antagonist, FK888, for cloned rat and human tachykinin receptors.
    Aramori I; Morikawa N; Zenkoh J; O'Donnell N; Iwami M; Kojo H; Notsu Y; Okuhara M; Ono S; Nakanishi S
    Eur J Pharmacol; 1994 Oct; 269(2):277-81. PubMed ID: 7531648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temperature and agonist dependency of tachykinin NK1 receptor antagonist potencies in rat isolated superior cervical ganglion.
    Hawcock AB; Beresford IJ; Marshall FH; Hagan RM
    Eur J Pharmacol; 1995 Dec; 294(1):163-71. PubMed ID: 8788428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of both NK1 and NK2 receptors in guinea-pig airways.
    McKee KT; Millar L; Rodger IW; Metters KM
    Br J Pharmacol; 1993 Oct; 110(2):693-700. PubMed ID: 7694756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gly166 in the NK1 receptor regulates tachykinin selectivity and receptor conformation.
    Ciucci A; Palma C; Riitano D; Manzini S; Werge TM
    FEBS Lett; 1997 Oct; 416(3):335-8. PubMed ID: 9373180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Typical and atypical NK1 tachykinin receptor characteristics in the rabbit isolated iris sphincter.
    Hall JM; Mitchell D; Morton IK
    Br J Pharmacol; 1994 Jul; 112(3):985-91. PubMed ID: 7522864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin A is a substance P (tachykinin NK1) receptor antagonist.
    Gitter BD; Waters DC; Threlkeld PG; Lovelace AM; Matsumoto K; Bruns RF
    Eur J Pharmacol; 1995 May; 289(3):439-46. PubMed ID: 7556412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist.
    Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Terracciano R; Fincham CI; Manzini S
    Eur J Pharmacol; 1998 Jan; 341(2-3):201-9. PubMed ID: 9543241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
    Hale JJ; Mills SG; MacCoss M; Finke PE; Cascieri MA; Sadowski S; Ber E; Chicchi GG; Kurtz M; Metzger J; Eiermann G; Tsou NN; Tattersall FD; Rupniak NM; Williams AR; Rycroft W; Hargreaves R; MacIntyre DE
    J Med Chem; 1998 Nov; 41(23):4607-14. PubMed ID: 9804700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.